The pathology of ocular cancer

Eye (Basingstoke)

Volumn 27, Issue 2, 2013, Pages 128-136

  Eagle, R C ^a,b  

^a WILLS EYE HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Eye cancer; Introduction; Retinoblastoma; Uveal melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 6; BRCA1 PROTEIN; G PROTEIN COUPLED RECEPTOR; RETINOBLASTOMA PROTEIN;

AUTOPSY; AUTOSOMAL DOMINANT INHERITANCE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CELL DIFFERENTIATION; CELL STRUCTURE; CHOROID TUMOR; CHROMOSOME 8; CILIARY BODY TUMOR; CONFERENCE PAPER; CYTODIAGNOSIS; DISOMY; ENUCLEATION; EPITHELIOID CELL; GENE EXPRESSION; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LYMPHOCYTIC INFILTRATION; MITOSIS; MONOSOMY; MULTIMODALITY CANCER THERAPY; OPTIC NERVE; PATHOGENESIS; PATHOLOGY; PHOTORECEPTOR; RETINOBLASTOMA; ROSETTE FORMING CELL; SOMATIC MUTATION; SPINDLE CELL; ULTRAVIOLET RADIATION; UVEA MELANOMA;

EID: 84874058850     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2012.237     Document Type: Conference Paper

References (63)

1. Nelson CC, Hertzberg BS, Klintworth GK. A histopathologic study of 716 unselected eyes in patients with cancer at the time of death. Am J Ophthalmol 1983; 95: 788-793
2. Kivelä T. The epidemiological challenge of the most frequent eye cancer: Retinoblastoma, an issue of birth and death. Brit J Ophthalmol 2009; 93: 1129-1131
3. Hu DN, Yu GP, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol 2005; 140: 612-617
4. Lists of Ethnic Groups. http://en.wikipedia.org/wiki/ Lists-of-ethnic-groups
5. Shah CP, Weis E, Lajous M, Shields JA, Shields CL. Intermittent and chronic ultraviolet light exposure and uveal melanoma: A meta-Analysis. Ophthalmology 2005; 112: 1599-1607
6. Schmidt-Pokrzywniak A, Jöckel KH, Bornfeld N, Sauerwein W, Stang A. Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma: A case-control study. Ophthalmology 2009; 116: 340-348
7. Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol 2009; 127: 989-998
8. Albert DM, Diener-West M, Robinson NL, Grossniklaus HE, Green WR. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol 1998; 125: 745-766
9. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008; 49: 5230-5234
10. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457: 599-602
11. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S,Wiesner Tet al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363: 2191-2199
12. Zuidervaart W, van der Velden PA, Hurks MH, van Nieuwpoort FA, Out-Luiting CJ, Singh AD et al. Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development. Br J Cancer 2003; 89: 1914-1919
13. Tschentscher F, Hüsing J, Hö lter T, Kruse E, Dresen IG, Jöckel KH et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003; 63: 2578-2584
14. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64: 7205-7209
15. Chang SH, Worley LA, Onken MD, Harbour JW. Prognostic biomarkers in uveal melanoma: Evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res 2008; 18: 191-200
16. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jöckel KH, Becher R et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347: 1222-1225
17. Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997; 19: 22-28
18. White VA, Chambers JD, Courtright PD, Chang WY, Horsman DE. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 1998; 83: 354-359
19. Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligationdependent probe amplification. Clin Cancer Res 2010; 16: 6083-6092
20. Shields CL, Ganguly A, Materin MA, Teixeira L, Mashayekhi A, Swanson LA et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: The Deborah Iverson, MD, Lectureship. Arch Ophthalmol 2007; 125: 1017-1024
21. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330: 1410-1413
22. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010; 12: 461-468
23. Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E et al. Collaborative Ocular Oncology Group report number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012; 119: 1596-1603
24. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti AM (eds). American Joint Commission on Cancer. Cancer Staging Manual. 7th Edition Springer: New York, 2010
25. McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: Location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 1982; 13: 123-132
26. Callender G. Malignant melanotic tumors of the eye: A study of histologic types in 111 cases. Trans Am Acad Ophthalmol Otolaryngol 1931; 36: 131-142
27. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 1983; 96: 502-509
28. Gamel JW, McLean IW. Quantitative analysis of the Callender classification of uveal melanoma cells. Arch Ophthalmol 1977; 95: 686-691
29. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: III. Initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001; 119: 969-982
30. Schmittel A, Bechrakis NE, Martus P, Mutlu D, Scheibenbogen C, Bornfeld N et al. Independent prognostic factors for distant metastases and survival in patients with primary uveal melanoma. Eur J Cancer 2004; 40: 2389-2395
31. McLean IW, Ainbinder DJ, Gamel JW, McCurdy JB. Choroidal-ciliary body melanoma. A multivariate survival analysis of tumor location. Ophthalmology 1995; 102: 1060-1064
32. Al-Jamal RT, Kivela T. KI-67 immunopositivity in choroidal and ciliary body melanoma with respect to nucleolar diameter and other prognostic factors. Curr Eye Res 2006; 31: 57-67
33. de la Cruz Jr. PO, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer 1990; 65: 112-115
34. Whelchel JC, Farah SE, McLean IW, Burnier MN. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci 1993; 34: 2603-2606
35. Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Tumorinfiltrating macrophages (CD68( cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001; 42: 1414-1421
36. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Woolson RF, Pe'er J, Gruman LM et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 1993; 100: 1389-1398
37. Makitie T, Summanen P, Tarkkanen A, Kivela T. Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 1999; 91: 359-367
38. Coupland SE, Campbell I, Damato B. Routes of extraocular extension of uveal melanoma: Risk factors and influence on survival probability. Ophthalmology 2008; 115: 1778-1785
39. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 2005; 123: 1639-1643
40. Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivelä T. Tumor doubling times in metastatic malignant melanoma of the uvea: Tumor progression before and after treatment. Ophthalmology 2000; 107: 1443-1449
41. Augsburger JJ, Corrêa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009; 148: 119-127
42. Shields CL, Shields JA, Shah P. Retinoblastoma in older children. Ophthalmology 1991; 98: 395-399
43. Dryja TP, Cavenee W, White R, Rapaport JM, Petersen R, Albert DM et al. Homozygosity of chromosome 13 in retinoblastoma. N Engl J Med 1984; 310: 550-553
44. Albert DM, Dryja TP. Recent studies of the retinoblastoma gene. What it means to the ophthalmologist. Arch Ophthalmol 1988; 106: 181-182
45. Brantley Jr. MA, Harbour JW. The molecular biology of retinoblastoma. Ocul Immunol Inflamm 2001; 9: 1-8
46. Abramson DH. Second nonocular cancers in retinoblastoma: A unified hypothesis. The Franceschetti Lecture. Ophthalmic Genet 1999; 20: 193-204
47. Meadows AT, Leahey AM. More about second cancers after retinoblastoma. J Natl Cancer Inst 2008; 100: 1743-1745
48. Dimaras H, Khetan V, Halliday W, Orlic M, Prigoda NL, Piovesan B et al. Loss of RB1 induces non-proliferative retinoma: Increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet 2008; 15(17): 1363-1372
49. Gallie BL, Rushlow DE, Yee JY, Kennett P, Boutros NL, Prigoda-Lee W et al. A new disease: Retinoblastoma with no detectable RB1 mutations driven by MYCN. Abstract. XVth Biannual Meeting. International Society of Ocular Oncology: Buenos Aires, Nov 14, 2011
50. Shields JA, Shields CL, Eagle RC, Blair CJ. Spontaneous pseudohypopyon secondary to diffuse infiltrating retinoblastoma. Arch Ophthalmol 1988; 106: 1301-1302
51. Shields JA, Shields CL, Suvarnamani C, Schroeder RP, DePotter P. Retinoblastoma manifesting as orbital cellulitis. Am J Ophthalmol 1991; 112: 442-449
52. Burnier MN, McLean IW, Zimmerman LE, Rosenberg SH. Retinoblastoma. The relationship of proliferating cells to blood vessels. Invest Ophthalmol Vis Sci 1990; 31: 2037-2040
53. Ts'o MO, Fine BS, Zimmerman LE. The Flexner-Wintersteiner rosettes in retinoblastoma. Arch Pathol 1969; 88: 664-671
54. Ts'o MO, Zimmerman LE, Fine BS. The nature of retinoblastoma. I. Photoreceptor differentiation: A clinical and histopathologic study. Am J Ophthalmol 1970; 69: 339-349
55. Ts'o MO, Fine BS, Zimmerman LE. The nature of retinoblastoma. II. Photoreceptor differentiation: An electron microscopic study. Am J Ophthalmol 1970; 69: 350-359
56. Eagle Jr. RC. High-risk features and tumor differentiation in retinoblastoma: A retrospective histopathologic study. Arch Pathol Lab Med 2009; 133: 1203-1209
57. Sastre X, Chantada GL, Doz F, Wilson MW, de Davila MT, Rodriguez-Galindo C et al. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med 2009; 133: 1199-1202
58. Che'vez-Barrios P. Pathology of high-risk retinoblastoma. In Ramasubrahmanian A, Shields CL (eds). Retinoblastoma. Jaypee: New Delhi, pp 223-230
59. Shields CL, Shields JA, De Potter P, Minelli S, Hernandez C, Brady LW et al. Plaque radiotherapy in the management of retinoblastoma. Use as a primary and secondary treatment [see comments]. Ophthalmology 1993; 100: 216-224
60. Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA et al. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol 2004;138: 329-337
61. Kaliki S, Shields CL, Shah SU, Eagle Jr. RC, Shields JA, Leahey A. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol 2011;129(11): 1422-1427
62. Eagle Jr. RC, Shields CL, Bianciotto C, Jabbour P, Shields JA. Histopathologic observations after intra-Arterial chemotherapy for retinoblastoma. Arch Ophthalmol 2011;129: 1416-1421
63. Munier FL, Gaillard MC, Balmer A, Soliman S, Podilsky G, Moulin AP et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: From prohibition to conditional indications. Br J Ophthalmol 2012;96: 1078-1083